Cargando…
CD47–SIRPα-targeted therapeutics: status and prospects
CD47 is a “don’t eat me” signal to phagocytes that is overexpressed on many tumor cells as a potential mechanism for immune surveillance evasion. CD47 and its interaction with signal-regulating protein alpha (SIRPα) on phagocytes is therefore a promising cancer target. Therapeutic antibodies and fus...
Autores principales: | Maute, R., Xu, J., Weissman, I.L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216458/ https://www.ncbi.nlm.nih.gov/pubmed/35754851 http://dx.doi.org/10.1016/j.iotech.2022.100070 |
Ejemplares similares
-
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021) -
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022) -
Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018) -
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
por: Qu, Tailong, et al.
Publicado: (2022) -
CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)